Navigation Links
Plant pathogen yields substance to fight neuroblastoma

Drug treatment of neuroblastoma, a tumor of the nervous system in children, poses major problems. Therefore, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been searching for substances that are suitable as a basis for developing better drugs. Now they have found a candidate: HC-toxin, which is isolated from a fungal plant pathogen. The substance from the maize pathogen reprograms neuroblastoma cells in such a way that they behave almost like healthy cells again.

Normally, the fungus Helminthosporium carbonum leads to reduced harvests for maize farmers. Yet a specific constituent of the pathogen, namely HC-toxin, might be very useful for medicine. The substance is used by scientists as a basis for developing a new anti-cancer drug. HC-toxin acts on enzymes known as histone deacetylases (HDACs), which structure the packaging of the genetic material, or DNA. HDAC enzymes change, among others, the histones proteins around which the DNA is wrapped. Alterations in the packaging of the genetic material are suspected to cause cancer or promote its spread. Therefore, scientists are studying substances that inhibit HDAC enzymes for their ability to fight malignant tumors.

Among these substances is HC-toxin, which has now been investigated by researchers of the Clinical Cooperation Unit Pediatric Oncology at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). They found out that neuroblastoma cells lose several of their cancer-typical properties when under the influence of the substance: They divide less frequently, show less invasive growth and even their outside appearance resembles healthy nerve cells again. These effects were observed to be stronger than with other HDAC inhibitors investigated previously.

The effect of HC-toxin is presumably based, among other things, on the fact that it promotes the function of an important cellular cancer brake known as RB signaling pathway. The investigators found out that the cancer brake was much more active in tumors cells that had been treated with HC-toxin than in untreated cells. They plan to conduct further research to determine whether the substance derived from the maize pathogen is suitable for developing a new drug to fight neuroblastoma.

Neuroblastoma is the second most frequent malignant tumor in children. With an average of 150 new cases diagnosed in Germany each year, neuroblastoma constitutes about seven to eight percent of all childhood cancers. Most affected children are in preschool age, one third are diagnosed under one year of age. Although treatment has been improved over the past few years, chances of recovery from advanced stage neuroblastoma continue to be very low. In addition, the drugs being used often cause serious side effects.


Contact: Dr. Sibylle Kohlstdt
Helmholtz Association of German Research Centres

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. Advanced Age No Bar to Liver Transplant
5. Nanowire coating for bone implants, stents
6. Circulating fats kill transplanted pancreas cells, study shows
7. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
8. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
9. Implantable device designed to detect, stop seizures under study at MCG
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. Bone-growing nanomaterial could improve orthopaedic implants
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... by the University of Toronto and the University of British Columbia suggested that laws ... head injuries. The article explains that part of the reason for the controversial conclusion ...
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A simply groundbreaking ... is an interesting show that delves into an array of issues that are presently ... could benefit from open dialogue, this show is changing the subjects consumers focus on, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology: